Inclusion is bigger than policy or workplace acronyms. It’s a way of living and fostering greater outcomes, writes Novo Nordisks Jill Fallows Macaluso.

Pharma and biotech companies can use AI to effectively and efficiently communicate with providers and patients, writes Jenna ...

In the July issue of Life Science Leader, Cliff Mintz wrote a global update on follow-on biologics in unregulated markets, the European Union, and the United States. With intense public debate around ...

In high-throughput biotech and pharmaceutical environments, achieving agility and precision is crucial, especially in functions like Environmental Monitoring (EM) and Sample Management. When these ...

On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during ...

Artificial intelligence is reshaping drug discovery, but its integration raises critical questions: How do we balance AI-driven insights with data integrity, human expertise, and ethical ...

Novartis is making a major investment in North Carolina’s Research Triangle, committing $771 million across three projects that will strengthen U.S. pharmaceutical manufacturing. The expansion ...

Advancements in science and technology, combined with unmet patient needs, are driving accelerated timelines and creative pathways for oncology drug development. While public desire for novel and ...

The term Big Data is on everyone’s lips, from retailers to healthcare providers. But what actually is it, and how can it help biopharma R&D? There are many definitions of Big Data, but perhaps the ...

Q3 2025 delivered meaningful momentum across the gene, cell, and RNA therapy landscape, highlighted by four global approvals. China’s NMPA cleared Hrain Biotechnology’s Hicara CAR-T for large B-cell ...

Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market.

2025 has been a whirlwind year thus far for the life sciences industry as the sector continues to grapple with a diverse set of evolving challenges. The simultaneous impacts of global trade shifts, ...